• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?利妥昔单抗维持治疗弥漫性大B细胞淋巴瘤：XY是最重要的变量吗？
Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.
2
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
3
[Richter syndrome: report of a case].[里氏综合征：一例报告]
Zhonghua Bing Li Xue Za Zhi. 2010 Jul;39(7):487-8.
4
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.外周血淋巴细胞/单核细胞比值可预测利妥昔单抗时代滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
5
Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.环磷酰胺、多柔比星、长春新碱和泼尼松方案联合聚乙二醇化脂质体多柔比星±利妥昔单抗治疗弥漫性大B细胞淋巴瘤的疗效和安全性。
Minerva Med. 2021 Apr;112(2):310-312. doi: 10.23736/S0026-4806.19.06236-0. Epub 2019 Jul 17.
6
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.免疫化疗是老年弥漫性大B细胞淋巴瘤患者的标准治疗方法。
Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. doi: 10.1182/blood-2004-04-1266.
7
[Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].[原发性子宫体弥漫性大B细胞淋巴瘤：一例报告]
Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):270-2.
8
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.增加利妥昔单抗（R）剂量可消除侵袭性CD20+B细胞淋巴瘤老年男性患者增加的风险并改善预后：德国淋巴瘤研究组（DSHNHL）的SEXIE-R-CHOP-14试验
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
9
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).在老年弥漫性大B细胞淋巴瘤患者中，R-CHOP诱导化疗四个周期后进行利妥昔单抗巩固治疗：淋巴瘤生存改善联盟研究（CISL）
Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.
10
CHOP plus rituximab--balancing facts and opinion.环磷酰胺、阿霉素、长春新碱、强的松联合利妥昔单抗——权衡事实与观点。
N Engl J Med. 2002 Jan 24;346(4):280-2. doi: 10.1056/NEJM200201243460411.

引用本文的文献

1
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.利妥昔单抗的药代动力学与抗中性粒细胞胞浆抗体相关性血管炎患者的临床结局。
Rheumatology (Oxford). 2018 Apr 1;57(4):639-650. doi: 10.1093/rheumatology/kex484.

本文引用的文献

1
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.利妥昔单抗用于一线缓解期侵袭性B细胞淋巴瘤患者的维持治疗：随机NHL13试验结果
Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.
2
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.增加利妥昔单抗（R）剂量可消除侵袭性CD20+B细胞淋巴瘤老年男性患者增加的风险并改善预后：德国淋巴瘤研究组（DSHNHL）的SEXIE-R-CHOP-14试验
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
3
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤的优化（二）：德国高级非霍奇金淋巴瘤研究组 SMARTE-R-CHOP-14 试验中延长利妥昔单抗暴露时间。
J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17.
4
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.利妥昔单抗与观察等待策略在晚期无症状非大肿块滤泡淋巴瘤患者中的比较：一项开放标签随机 3 期试验。
Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4.
5
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.利妥昔单抗维持治疗与观察对年龄大于 60 岁的晚期滤泡淋巴瘤患者一线 R-FND 化疗免疫联合利妥昔单抗巩固治疗后的影响：一项由意大利淋巴瘤基金会开展的 III 期随机研究。
J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19.
6
Treatment of older patients with mantle-cell lymphoma.治疗老年套细胞淋巴瘤患者。
N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.
7
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.性别和体重对老年弥漫性大 B 细胞淋巴瘤患者利妥昔单抗清除率和血清消除半衰期的作用。
Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15.
8
How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.弥漫大 B 细胞淋巴瘤成人患者接受 RCHOP 治疗后的风险分层，维持性利妥昔单抗治疗或观察：多中心经验。
J Cancer Res Clin Oncol. 2012 Jan;138(1):125-32. doi: 10.1007/s00432-011-1074-1. Epub 2011 Nov 6.
9
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
10
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.在环磷酰胺、长春新碱和泼尼松治疗后使用利妥昔单抗维持治疗可延长晚期惰性淋巴瘤的无进展生存期：III期随机ECOG1496研究结果
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.

Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?

作者信息

Lunning Matthew A, Armitage James O

机构信息

University of Nebraska Medical Center, Internal Medicine Department, Hematology/Oncology Division, Omaha, NE, USA.

University of Nebraska Medical Center, Internal Medicine Department, Hematology/Oncology Division, Omaha, NE, USA

出版信息

Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.

DOI:10.3324/haematol.2015.129924
PMID:26130511
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4486218/
Abstract
摘要